SCHEMBL35142

SCHEMBL35142

Nc1c(Cl)cccc1C(=O)c1cccc(O)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B1 P14061 6/20 0.49
HSD17B2 P37059 6/20 0.49
PARP1 P09874 1/20 0.49
FASN P49327 1/20 0.47
CLK1 P49759 2/20 0.46
DYRK1A Q13627 2/20 0.46
DYRK1B Q9Y463 2/20 0.46
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA6 P23280 1/20 0.46
CA9 Q16790 1/20 0.46
SIRT1 Q96EB6 1/20 0.46
ALDH1A1 P00352 2/20 0.45
KDM4E B2RXH2 2/20 0.45
POLB P06746 1/20 0.44
STS P08842 1/20 0.43
FGFR1 P11362 1/20 0.43
SRC P12931 1/20 0.43
FGFR2 P21802 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15628209 0.85 ALOX15 (0.54) PARP1ALDH1A1POLB
SCHEMBL31366601 0.83 GAA (0.58) ALDH1A1POLB
SCHEMBL1569037 0.83 GAA (0.58) ALDH1A1POLB
SCHEMBL15608527 0.83 POLB (0.58) PARP1ALDH1A1KDM4EPOLBFGFR1
SCHEMBL4014144 0.81 PARP1 (0.49) HSD17B1HSD17B2PARP1FASNCLK1
SCHEMBL28620541 0.79 FASN (0.53) HSD17B1HSD17B2PARP1FASNCLK1
SCHEMBL15608444 0.78 ALDH1A1 (0.56) ALDH1A1KDM4EPOLB
SCHEMBL11320848 0.78 NR4A1 (0.56) ALDH1A1POLB
SCHEMBL8080314 0.78 MAPT (0.67) HSD17B1HSD17B2PARP1FASNCLK1
SCHEMBL15608481 0.78 KMO (0.46) PARP1ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2590948-A1 NOVEL QUINOLINE ESTERS USEFUL FOR TREATING SKIN DISORDERS Wyeth LLC (US) 2013-05-15 EP disclosed
WO-2012004748-A1 NOVEL QUINOLINE ESTERS USEFUL FOR TREATING SKIN DISORDERS WYETH LLC (US) 2012-01-12 WO disclosed
WO-2012004748-A1 NOVEL QUINOLINE ESTERS USEFUL FOR TREATING SKIN DISORDERS WYETH LLC (US) 2012-01-12 WO disclosed
US-20120010205-A1 NOVEL QUINOLINE ESTERS USEFUL FOR TREATING SKIN DISORDERS WYETH LLC (US) 2012-01-12 US disclosed
US-20120010205-A1 NOVEL QUINOLINE ESTERS USEFUL FOR TREATING SKIN DISORDERS WYETH LLC (US) 2012-01-12 US disclosed
US-20120010205-A1 NOVEL QUINOLINE ESTERS USEFUL FOR TREATING SKIN DISORDERS WYETH LLC (US) 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010205-A1 NOVEL QUINOLINE ESTERS USEFUL FOR TREATING SKIN DISORDERS NR1H2, NR1H3, NR1H4 HSD17B1 69/4885HSD17B2 88/4885PARP1 3438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.